Despite some limitations, this observational cohort study suggests that continuing treatment with DMTs such as teriflunomide, IFNB, and fingolimod, as well as immunosuppressants such as mycophenolate mofetil and azathioprine, during the pandemic might be safe for patients with MS who use recommended COVID-19 preventive approaches, while withdrawal of the above treatments during the pandemic definitely increases MS disease activity. This evidence concerns the gene IFNB1 and myeloid sarcoma.